A new independent 773 page research with title ‘Colon Cancer – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis and important players/vendors such as HitGen LTD,Horizon Pharma etc. With n-number of tables and figures examining the Colon Cancer , the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/841034-colon-cancer-pipeline-review-1
The latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Pipeline Review, H2 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape.
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
The Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 41, 5, 163, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 46 and 17 molecules, respectively.
Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=841034
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned in the Report
3-V Biosciences Inc,4P-Pharma SAS,Actinium Pharmaceuticals Inc,Adamed Sp z oo,Adgero Biopharmaceuticals Holdings Inc,Aduro BioTech Inc,Advanced Cancer Therapeutics LLC,Advenchen Laboratories LLC,Aeglea BioTherapeutics Inc,Affimed GmbH,AGV Discovery SAS,AIMM Therapeutics BV,Ambrx Inc,Amgen Inc,Anavex Life Sciences Corp,AndroScience Corp,ANP Technologies Inc,Aphios Corp,Aposense Ltd,Aptose Biosciences Inc,Asana BioSciences LLC,Aurigene Discovery Technologies Ltd,Batu Biologics Inc,Bayer AG,BCN Biosciences LLC,BeyondSpring Pharmaceuticals Inc,Bicycle Therapeutics Ltd,BioCancell Ltd,Biogazelle NV,Blirt SA,Boehringer Ingelheim GmbH,Can-Fite BioPharma Ltd,CBT Pharmaceuticals Inc,Celgene Corp,Celprogen Inc,Critical Outcome Technologies Inc,CrystalGenomics Inc,CytomX Therapeutics Inc,Cytune Pharma SAS,CZ BioMed Corp,Debiopharm International SA,DEKK-TEC Inc,Eli Lilly and Co,EntreChem SL,EnzymeBioSystems,F-star Biotechnology Ltd,Felicitex Therapeutics Inc,G1 Therapeutics Inc,GlaxoSmithKline Plc,GlycaNova Norway AS,GlycoMimetics Inc,Grunenthal GmbH,Halozyme Therapeutics Inc,Hamlet Pharma AB,Hanmi Pharmaceuticals Co Ltd,Histogen Inc,HitGen LTD,Horizon Pharma Plc,Hummingbird Bioscience Pte Ltd,Idera Pharmaceuticals Inc,Immix BioPharma Inc,Immune Pharmaceuticals Inc,Immunomedics Inc,Immunotope Inc,IMPACT Therapeutics Inc,Infinity Pharmaceuticals Inc,Innopharmax Inc,Intezyne Technologies Inc,Ironwood Pharmaceuticals Inc,Jasco Pharmaceuticals LLC,Jiangsu Kanion Pharmaceutical Co Ltd,JW Pharmaceutical Corp,Karyopharm Therapeutics Inc,Kineta Inc,Kringle Pharma Inc,Kyowa Hakko Kirin Co Ltd,Lipocure Ltd,Lixte Biotechnology Holdings Inc,Lupin Ltd,Lymphocyte Activation Technologies SA,MabVax Therapeutics Holdings Inc,MacroGenics Inc,Madrigal Pharmaceuticals Inc.,MaxiVAX SA,Medicenna Therapeutics Corp,Merus NV,Microlin Bio Inc,Molecular Targeting Technologies Inc,MolMed SpA,Mologen AG,Monopar Therapeutics LLC,Multimmune GmbH,Nektar Therapeutics,Northwest Biotherapeutics Inc,Novartis AG,OncoResponse Inc,Oncovir Inc,Ono Pharmaceutical Co Ltd,Orega Biotech SAS,OSE Immunotherapeutics,Panacea Pharmaceuticals Inc,Patrys Ltd,PharmaCyte Biotech Inc,Philogen SpA,Plexxikon Inc,Prosetta Biosciences Inc,Provecs Medical GmbH (Inactive),Provectus Biopharmaceuticals Inc,Qu Biologics Inc,Redx Pharma Plc,Rexahn Pharmaceuticals Inc,Rgenix Inc,Sareum Holdings Plc,Sierra Oncology Inc,Sigma-Tau SpA,Sirnaomics Inc,Somantix BV,Sorrento Therapeutics Inc,Spring Bank Pharmaceuticals Inc,Starpharma Holdings Ltd,Synergys Biotherapeutics Inc,Systimmune Inc,Taiwan Liposome Company Ltd,Takis Srl,Theravectys SA,Tiziana Life Sciences Plc,Transgene Biotek Ltd,TVAX Biomedical Inc,Tyg Oncology Ltd,Vaccibody AS,Vaccinogen Inc,Vault Pharma Inc,Vaxenta Biotechnologies,Vernalis Plc,VG Life Sciences Inc,Vivolux AB,Yakult Honsha Co Ltd,Zenith Epigenetics Ltd,ZIOPHARM Oncology Inc
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/841034-colon-cancer-pipeline-review-1
Table of Contents
Colon Cancer – Overview 8
Colon Cancer – Therapeutics Development 9
Colon Cancer – Therapeutics Assessment 43
Colon Cancer – Companies Involved in Therapeutics Development 67
Colon Cancer – Drug Profiles 126
Colon Cancer – Dormant Projects 718
Colon Cancer – Discontinued Products 730
Colon Cancer – Product Development Milestones 731
Appendix 741List of Tables
Number of Products under Development for Colon Cancer, H2 2017 40
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/841034-colon-cancer-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218